Nancy A Wilson1, Natalie M Bath2, Bret M Verhoven2, Xiang Ding3, Brittney A Boldt2, Adarsh Sukhwal3, Weixiong Zhong4, Sarah E Panzer1, Robert R Redfield2. 1. Division of Nephrology, Department of Medicine, University of Wisconsin-Madison, Madison, WI. 2. Division of Transplant, Department of Surgery, University of Wisconsin-Madison, Madison, WI. 3. Department of Organ Transplantation, Xiangya Hospital, Central South University, Changsha, China. 4. Department of Pathology, University of Wisconsin-Madison, Madison, WI.
Abstract
BACKGROUND: Highly sensitized candidates on the transplant waitlist remain a significant challenge, as current desensitization protocols have variable success rates of donor-specific antibody (DSA) reduction. Therefore, improved therapies are needed. A proliferation-inducing ligand (APRIL) and B-lymphocyte stimulator (BLyS) are critical survival factors for B-lymphocytes and plasma cells, which are the primary sources of alloantibody production. We examined the effect of APRIL/BLyS blockade on DSA in a murine kidney transplant model as a possible novel desensitization strategy. METHODS: C57BL/6 mice were sensitized with intraperitoneal (IP) injections of 2 × 10 BALB/c splenocytes. Twenty-one days following sensitization, animals were treated with 100 μg of BLyS blockade (B-cell activating factor receptor-immunoglobulin) or APRIL/BLyS blockade (transmembrane activator and calcium modulator and cyclophilin ligand interactor-immunoglobulin), administered thrice weekly for an additional 21 days. Animals were then euthanized or randomized to kidney transplant with Control Ig, BLyS blockade, or APRIL/BLyS blockade. Animals were euthanized 7 days posttransplant. B-lymphocytes and DSA of BLyS blockade only or APRIL/BLyS blockade-treated mice were assessed by flow cytometry, immunohistochemistry, and enzyme-linked immunospot. RESULTS: APRIL/BLyS inhibition resulted in a significant reduction of DSA by flow crossmatch compared with controls (P < 0.01). APRIL/BLyS blockade also significantly depleted IgM- and IgG-secreting cells and B-lymphocyte populations compared to controls (P < 0.0001). APRIL/BLyS blockade in transplanted mice also resulted in decreased B-lymphocyte populations; however, no difference in rejection rates were seen between groups. CONCLUSIONS: APRIL/BLyS blockade with transmembrane activator and calcium modulator and cyclophilin ligand interactor-immunoglobulin significantly depleted B-lymphocytes and reduced DSA in this sensitized murine model. APRIL/BLyS inhibition may be a clinically useful desensitization strategy for sensitized transplant candidates.
BACKGROUND: Highly sensitized candidates on the transplant waitlist remain a significant challenge, as current desensitization protocols have variable success rates of donor-specific antibody (DSA) reduction. Therefore, improved therapies are needed. A proliferation-inducing ligand (APRIL) and B-lymphocyte stimulator (BLyS) are critical survival factors for B-lymphocytes and plasma cells, which are the primary sources of alloantibody production. We examined the effect of APRIL/BLyS blockade on DSA in a murine kidney transplant model as a possible novel desensitization strategy. METHODS: C57BL/6 mice were sensitized with intraperitoneal (IP) injections of 2 × 10 BALB/c splenocytes. Twenty-one days following sensitization, animals were treated with 100 μg of BLyS blockade (B-cell activating factor receptor-immunoglobulin) or APRIL/BLyS blockade (transmembrane activator and calcium modulator and cyclophilin ligand interactor-immunoglobulin), administered thrice weekly for an additional 21 days. Animals were then euthanized or randomized to kidney transplant with Control Ig, BLyS blockade, or APRIL/BLyS blockade. Animals were euthanized 7 days posttransplant. B-lymphocytes and DSA of BLyS blockade only or APRIL/BLyS blockade-treated mice were assessed by flow cytometry, immunohistochemistry, and enzyme-linked immunospot. RESULTS: APRIL/BLyS inhibition resulted in a significant reduction of DSA by flow crossmatch compared with controls (P < 0.01). APRIL/BLyS blockade also significantly depleted IgM- and IgG-secreting cells and B-lymphocyte populations compared to controls (P < 0.0001). APRIL/BLyS blockade in transplanted mice also resulted in decreased B-lymphocyte populations; however, no difference in rejection rates were seen between groups. CONCLUSIONS: APRIL/BLyS blockade with transmembrane activator and calcium modulator and cyclophilin ligand interactor-immunoglobulin significantly depleted B-lymphocytes and reduced DSA in this sensitized murine model. APRIL/BLyS inhibition may be a clinically useful desensitization strategy for sensitized transplant candidates.
Authors: William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham Journal: Arthritis Rheum Date: 2012-07
Authors: K A Newell; A Asare; I Sanz; C Wei; A Rosenberg; Z Gao; S Kanaparthi; S Asare; N Lim; M Stahly; M Howell; S Knechtle; A Kirk; W H Marks; T Kawai; T Spitzer; N Tolkoff-Rubin; M Sykes; D H Sachs; A B Cosimi; W J Burlingham; D Phippard; L A Turka Journal: Am J Transplant Date: 2015-10-13 Impact factor: 8.086
Authors: M A Mujtaba; W J Komocsar; E Nantz; M D Samaniego; S L Henson; J A Hague; A L Lobashevsky; N G Higgins; M Czader; B K Book; M D Anderson; M D Pescovitz; T E Taber Journal: Am J Transplant Date: 2016-01-18 Impact factor: 8.086
Authors: Robert A Montgomery; Bonnie E Lonze; Karen E King; Edward S Kraus; Lauren M Kucirka; Jayme E Locke; Daniel S Warren; Christopher E Simpkins; Nabil N Dagher; Andrew L Singer; Andrea A Zachary; Dorry L Segev Journal: N Engl J Med Date: 2011-07-28 Impact factor: 91.245
Authors: B Schiemann; J L Gommerman; K Vora; T G Cachero; S Shulga-Morskaya; M Dobles; E Frew; M L Scott Journal: Science Date: 2001-08-16 Impact factor: 47.728
Authors: H Wang; S A Marsters; T Baker; B Chan; W P Lee; L Fu; D Tumas; M Yan; V M Dixit; A Ashkenazi; I S Grewal Journal: Nat Immunol Date: 2001-07 Impact factor: 25.606
Authors: Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan Journal: N Engl J Med Date: 2008-07-17 Impact factor: 91.245
Authors: S Shabir; J Girdlestone; D Briggs; B Kaul; H Smith; S Daga; S Chand; S Jham; C Navarrete; L Harper; S Ball; R Borrows Journal: Am J Transplant Date: 2015-03-23 Impact factor: 8.086
Authors: Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle Journal: J Exp Med Date: 2004-01-05 Impact factor: 14.307
Authors: Nancy A Wilson; James Dylewski; Kenna R Degner; Megan A O'Neill; Shannon R Reese; Luis G Hidalgo; Judith Blaine; Sarah E Panzer Journal: Transpl Immunol Date: 2019-12-27 Impact factor: 1.708
Authors: Shannon R Reese; Nancy A Wilson; Yabing Huang; Lucille Ptak; Kenna R Degner; Ding Xiang; Robert R Redfield; Weixiong Zhong; Sarah E Panzer Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385
Authors: Natalie M Bath; Xiang Ding; Bret M Verhoven; Nancy A Wilson; Lauren Coons; Adarsh Sukhwal; Weixiong Zhong; Robert R Redfield Iii Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240